ALIVE Trial Summary: Amiodarone or Lidocaine in VFib

alive trial

2002 ALIVE TRIAL Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular Fibrillation Prospective, randomized, controlled, double-dummy trial Objective: To determine whether amiodarone compared with lidocaine could improve survival rates to hospital admission in patients with shock-refractory, out-of-hospital cardiac arrest. 344 adults with documented out-of-hospital ventricular fibrillation (VF); suffered persistent/recurrent VF despite three defibrillation shocks, epinephrine infusion (1.0 mg), and fourth shock 22.8 5 IV amiodarone (n = 179) VS IV lidocaine (n=165) PRIMARY OUTCOME Survival to admission to the hospital % OR 2.17; 95% CI, 1.21 to 3.83, P=0.009 SECONDARY OUTCOME Survival to discharge from the hospital % P=0.34 12.0 24 Treatment for bradycardia (atropine) after study drug % P=NS 23 Conclusion: As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital VF. Dorian P, et al. N Engl J Med. 2002. 346:884-890

Comments are closed.